Please login to the form below

Not currently logged in

Valeant makes $312m OraPharma acquisition

Takes control of gum disease treatment Arestin and Listerine family

Arestin - Valeant OraPhama

Valeant Pharmaceuticals has continued its run of acquisitions with the purchase of oral health company OraPharma.

Canadian pharma firm Valeant will make an initial payment of $312m to OraPharma's owners Water Street Healthcare Partners, with the cost potentially increasing by $114m depending on certain milestones.

The transaction, which is expected to close by the end of June 2012, will see Valeant take control of OraPharma's lead product, Arestin (minocycline hydrochloride) – an antiobiotic to treat gum disease, and the Listerine family of mouthwashes, which OraPharma markets in partnership with Johnson & Johnson (J&J).

According to Valeant, OraPharma's net revenue for the previous 12 months was $95m, with business growing at a single digit rate.

The oral health market is new territory for Valeant, although chair and CEO J Michael Pearson was confident of the acquisition's potential based on experience in related areas.

He said: "We believe that this market segment has similar characteristics to the dermatology, podiatry and ophthalmology markets and should offer us the opportunity to cross-sell some of our current products, most notably our new topical prescription cold sore medication, Xerese.

“We believe the OraPharma business is a new growth platform from which to build additional opportunities in the future."

Valeant has expanded into several therapy areas and geographies in recent months, paying $27m for footcare specialist Pedinol Pharmacal in April, 2012 and acquiring Russian OTC company Natur Produkt for $180, in a deal that gave Valeant control of several cough and cold remedies.

Other moves into Russia for Valeant include the acquisition of a portfolio of generics drugs from Austria-based Gerot Lannach and which are sold in Russia.

18th June 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....